{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:08:45Z","timestamp":1794506925280,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","award":["R-982223"],"award-info":[{"award-number":["R-982223"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to identify predictors of renal flares in patients with SLE treated for active extra-renal disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from four clinical trials of belimumab in SLE (BLISS-52, NCT00424476; BLISS-76, NCT00410384; BLISS-NEA, NCT01345253; BLISS-SC, NCT01484496) were used. Patients were assigned to belimumab or placebo on top of standard therapy. We investigated the performance of predictors of renal flares through weeks 52\u201376 using proportional hazards regression analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 3225 participants, 192 developed at least one renal flare during follow-up, with the first occurring after a median time of 197\u2009days. Current\/former renal involvement [hazards ratio (HR): 15.4; 95% CI: 8.3\u201328.2; P\u2009&amp;lt;\u20090.001], low serum albumin levels (HR 0.9; 95% CI: 0.8\u20130.9; P\u2009&amp;lt;\u20090.001), proteinuria (HR: 1.6; 95% CI: 1.5\u20131.7; P\u2009&amp;lt;\u20090.001), and low C3 levels (HR: 2.9; 95% CI: 2.1\u20134.1; P\u2009&amp;lt;\u20090.001) at baseline appeared robust determinants of impending renal flares. Anti-dsDNA positivity yielded an increased hazard for renal flares (HR: 2.1; 95% CI: 1.4\u20133.2; P\u2009&amp;lt;\u20090.001), which attenuated after adjustments. Anti-Sm positivity was associated with renal flares in the placebo (HR: 3.7; 95% CI: 2.0\u20136.9; P\u2009&amp;lt;\u20090.001) but not in the belimumab subgroup, whereas anti-ribosomal P positivity was associated with renal flares in the belimumab subgroup only (HR: 2.8; 95% CI: 1.5\u20135.0; P\u2009=\u20090.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A history of renal involvement, high baseline proteinuria, hypoalbuminaemia, and C3 consumption were robust determinants of impending renal flares. In addition to anti-dsDNA, anti-Sm and anti-ribosomal P protein antibody positivity may have value in surveillance of renal SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae023","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T04:03:02Z","timestamp":1705118582000},"page":"623-631","source":"Crossref","is-referenced-by-count":13,"title":["Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab"],"prefix":"10.1093","volume":"64","author":[{"given":"Sandra","family":"J\u00e4gerback","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Division of Rheumatology, Department of Medicine, Danderyd University Hospital , Danderyd,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-1755","authenticated-orcid":false,"given":"Alvaro","family":"Gomez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital , Stockholm,","place":["Sweden"]},{"name":"Department of Rheumatology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"2025032905210175300_keae023-B1","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025032905210175300_keae023-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025032905210175300_keae023-B3","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1001\/archinte.160.20.3136","article-title":"Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995","volume":"160","author":"Ward","year":"2000","journal-title":"Arch Intern Med"},{"key":"2025032905210175300_keae023-B4","doi-asserted-by":"crossref","first-page":"e000389","DOI":"10.1136\/lupus-2020-000389","article-title":"Prediction of prognosis and renal outcome in lupus nephritis","volume":"7","author":"Parodis","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025032905210175300_keae023-B5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025032905210175300_keae023-B6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","article-title":"Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective","volume":"90","author":"Hoover","year":"2016","journal-title":"Kidney Int"},{"key":"2025032905210175300_keae023-B7","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/ki.1996.528","article-title":"\"Nephritic flares\" are predictors of bad long-term renal outcome in lupus nephritis","volume":"50","author":"Moroni","year":"1996","journal-title":"Kidney Int"},{"key":"2025032905210175300_keae023-B8","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2025032905210175300_keae023-B9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3389\/fimmu.2019.01667","article-title":"Anti-double Stranded DNA Antibodies: origin, Pathogenicity, and Targeted Therapies","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"2025032905210175300_keae023-B10","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025032905210175300_keae023-B11","doi-asserted-by":"crossref","first-page":"952304","DOI":"10.3389\/fmed.2022.952304","article-title":"B cells in systemic lupus erythematosus: targets of new therapies and surveillance tools","volume":"9","author":"Parodis","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025032905210175300_keae023-B12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.kint.2021.09.012","article-title":"The lupus nephritis management renaissance","volume":"101","author":"Mejia-Vilet","year":"2022","journal-title":"Kidney Int"},{"key":"2025032905210175300_keae023-B13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-017-1442-6","article-title":"Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review","volume":"19","author":"Gensous","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025032905210175300_keae023-B14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3899\/jrheum.140677","article-title":"Four Anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity","volume":"42","author":"Enocsson","year":"2015","journal-title":"J Rheumatol"},{"key":"2025032905210175300_keae023-B15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"2025032905210175300_keae023-B16","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025032905210175300_keae023-B17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025032905210175300_keae023-B18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025032905210175300_keae023-B19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025032905210175300_keae023-B20","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa051135","article-title":"Combined oral contraceptives in women with systemic lupus erythematosus","volume":"353","author":"Petri","year":"2005","journal-title":"N Engl J Med"},{"key":"2025032905210175300_keae023-B21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025032905210175300_keae023-B22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905210175300_keae023-B23","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025032905210175300_keae023-B24","article-title":"Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials","author":"Gomez","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905210175300_keae023-B25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905210175300_keae023-B26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ekir.2023.06.021","article-title":"Effect of Belimumab on Preventing de novo Renal Lupus Flares","volume":"8","author":"Parodis","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025032905210175300_keae023-B27","doi-asserted-by":"crossref","first-page":"e000260","DOI":"10.1136\/lupus-2018-000260","article-title":"TNF-\u03b1 and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus","volume":"5","author":"Idborg","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2025032905210175300_keae023-B28","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2665-9913(22)00307-1","article-title":"Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study","volume":"4","author":"Connelly","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"2025032905210175300_keae023-B29","doi-asserted-by":"crossref","first-page":"13941","DOI":"10.3390\/ijms232213941","article-title":"B cell kinetics upon therapy commencement for active extrarenal systemic lupus erythematosus in relation to development of renal flares: results from three phase III clinical trials of belimumab","volume":"23","author":"Parodis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025032905210175300_keae023-B30","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/j.ekir.2022.09.012","article-title":"Persistent isolated C3 hypocomplementemia as a strong predictor of end-stage kidney disease in lupus nephritis","volume":"7","author":"Rossi","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025032905210175300_keae023-B31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2011.332","article-title":"Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis","volume":"81","author":"Sargsyan","year":"2012","journal-title":"Kidney Int"},{"key":"2025032905210175300_keae023-B32","first-page":"2157","article-title":"Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways","volume":"6","author":"Kim","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"2025032905210175300_keae023-B33","first-page":"187","article-title":"Biomarker discovery in human SLE nephritis","volume":"65","author":"Rovin","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"2025032905210175300_keae023-B34","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00296-011-1962-3","article-title":"Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4","volume":"32","author":"Julkunen","year":"2012","journal-title":"Rheumatol Int"},{"key":"2025032905210175300_keae023-B35","first-page":"1495","article-title":"Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus","volume":"30","author":"Mannik","year":"2003","journal-title":"J Rheumatol"},{"key":"2025032905210175300_keae023-B36","first-page":"598","article-title":"What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3","volume":"35","author":"Flechsig","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025032905210175300_keae023-B37","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.3390\/ijms21103463","article-title":"Autoantibody and cytokine profiles during treatment with belimumab in patients with systemic lupus erythematosus","volume":"21","author":"Parodis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025032905210175300_keae023-B38","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/art.21875","article-title":"Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis","volume":"54","author":"do Nascimento","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025032905210175300_keae023-B39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1574887113666180409154641","article-title":"Clinical significance of anti-ribosomal P protein antibodies in patients with lupus nephritis","volume":"13","author":"Sarfaraz","year":"2018","journal-title":"Rev Recent Clin Trials"},{"key":"2025032905210175300_keae023-B40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2017.02.005","article-title":"Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus","volume":"16","author":"Parodis","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025032905210175300_keae023-B41","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/annrheumdis-2018-214880","article-title":"Established organ damage reduces belimumab efficacy in systemic lupus erythematosus","volume":"78","author":"Parodis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025032905210175300_keae023-B42","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2019-216367","article-title":"Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus","volume":"79","author":"Chatzidionysiou","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025032905210175300_keae023-B43","doi-asserted-by":"crossref","first-page":"e0158076","DOI":"10.1371\/journal.pone.0158076","article-title":"Antiphospholipid antibodies in lupus nephritis","volume":"11","author":"Parodis","year":"2016","journal-title":"PLoS One"},{"key":"2025032905210175300_keae023-B44","doi-asserted-by":"crossref","first-page":"e000061","DOI":"10.1136\/lupus-2014-000061","article-title":"Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy","volume":"2","author":"Parodis","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2025032905210175300_keae023-B45","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025032905210175300_keae023-B46","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025032905210175300_keae023-B47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ndt\/gfx220","article-title":"Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus","volume":"33","author":"Friebus-Kardash","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025032905210175300_keae023-B48","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0961203313496302","article-title":"Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus","volume":"22","author":"Vincent","year":"2013","journal-title":"Lupus"},{"key":"2025032905210175300_keae023-B49","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","article-title":"Overexpression of the cytokine BAFF and autoimmunity risk","volume":"376","author":"Steri","year":"2017","journal-title":"N Engl J Med"},{"key":"2025032905210175300_keae023-B50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12882-019-1623-4","article-title":"Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis","volume":"20","author":"Friebus-Kardash","year":"2019","journal-title":"BMC Nephrol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae023\/56533230\/keae023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/623\/56533230\/keae023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/623\/56533230\/keae023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:27:33Z","timestamp":1743391653000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/2\/623\/7521404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,12]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae023","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,1,12]]}}}